Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024

Contineum Therapeutics, Inc.

Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.
Boyce currently President & CEO of Avidity Biosciences (RNA); past roles include Akcea, Ionis, Forest Labs.
As non-employee director, receives standard compensation including initial option for 29,500 Class A shares.
Replaces Lori Lyons-Williams as Committee Chair; Lyons-Williams remains a member of the committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sarah Boyce

Class I Director and Chair of Nominating and Corporate Governance Committee

CTNM · Contineum Therapeutics, Inc.

Effective: 2024-06-24
Filed: June 24, 2024, 7:59 PM ET

On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Boyce was appointed as Class I Director and Chair of Nominating and Corporate Governance Committee at Contineum Therapeutics, Inc..

Action: appointed
Role: Class I Director and Chair of Nominating and Corporate Governance Committee

Exact text from the filing

On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.

View on SEC.gov

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-021083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.